Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN

NCT00022412 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT00022412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2001
Completion date
August 31, 2008
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer